GET DAILY SIGNALSInMode Ltd. (INMD): RF Technology and Recurring Revenue in Medical Aesthetics
Key Takeaways
- INMD is the Nasdaq ticker for InMode Ltd., an Israeli medical technology company that develops and sells minimally invasive and non-invasive aesthetic devices.
- The company's proprietary radio frequency (RF) technology is used across plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
- InMode generates revenue primarily by selling hardware platforms and related consumables, with the United States as its largest market.
- The company is known for its high gross margins and a cash-rich balance sheet, while facing a competitive and discretionary-spending-driven industry.
- Investors follow INMD for its innovative device portfolio, recurring consumable sales, and long-term positioning in the medical aesthetics market.
Introduction
InMode Ltd. designs, develops, manufactures, and markets energy-based devices for aesthetic and medical procedures. Trading on the Nasdaq under the ticker INMD, the company has centered its business on proprietary radio frequency (RF) technology that supports minimally invasive procedures with smaller incisions and shorter recovery times than traditional surgery. Because its products sit at the intersection of healthcare and elective aesthetics, InMode draws attention from investors focused on medical innovation, recurring revenue models, and the broader aesthetics industry. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Overview and History
InMode was incorporated in 2008 in Israel, where it remains headquartered in Yokne'am. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017 before completing its initial public offering (IPO) on the Nasdaq in 2019. InMode is led by co-founder and Chief Executive Officer Moshe Mizrahy, with co-founder Dr. Michael Kreindel serving as Chief Technology Officer.
The company's core technology is radio frequency assisted lipolysis and deep subdermal fractional RF, which it uses to develop platforms for body and facial contouring, skin tightening, and tissue remodeling. Over time, InMode has expanded its product line into three main categories: minimally invasive platforms, non-invasive platforms, and hands-free platforms. From what I see, the evolution of these platforms reflects a consistent focus on clinical applications.
Business Model and Revenue Sources
InMode's business model centers on selling capital equipment—the device platforms themselves—alongside disposable, single-use consumables and handpieces that physicians must continue purchasing to perform procedures. This creates a "razor-and-blade" dynamic in which each installed platform can drive ongoing, recurring consumable revenue after the initial hardware sale.
Its most recognizable brand is Morpheus8, a fractional RF microneedling technology used for skin rejuvenation and remodeling, though the company offers a broad portfolio spanning liposuction with simultaneous skin tightening, body and face contouring, ablative skin rejuvenation, hair reduction, cellulite treatment, and women's health applications. The company reports having dozens of U.S. Food and Drug Administration (FDA) clearances and sells through both a direct sales force and a network of distributors across more than 100 countries. I’m watching this closely because the recurring element stands out in the financial profile.
Market Position and Financial Profile
InMode has historically been distinguished by an unusually strong financial profile for a medical device maker, including gross margins that have generally remained well above 70% and a balance sheet carrying substantial cash and marketable securities with minimal debt. Its largest market is the United States, with international sales making up the remainder of revenue.
Like many companies in elective aesthetics, InMode's revenue is sensitive to consumer and physician spending cycles. The company's reported revenue has fluctuated in recent years as demand patterns shifted, even as it has continued to generate profits and cash flow. Its competitive positioning rests on its proprietary RF technology, a large installed base of platforms, and an emphasis on clinical evidence and physician training. One thing that stands out is how the cash position supports ongoing development.
Why Investors Follow INMD
Investors follow INMD for several long-term reasons. First, the company's installed base and consumable sales create a degree of recurring revenue that is less common among one-time capital equipment sellers. Second, its proprietary RF technology and regulatory clearances provide a competitive moat in a specialized segment of medical technology. Third, its cash-rich, low-debt balance sheet gives it financial flexibility for research and development, share repurchases, or other strategic initiatives. Finally, the broader medical aesthetics market is supported by long-term demographic and consumer trends favoring non-surgical and minimally invasive procedures, which positions InMode within a growing addressable market. I also checked this using Tickeron’s AI Trend Prediction Engine to review longer-term patterns.
Risks and Important Considerations
Investing in INMD carries several considerations. Aesthetic procedures are generally elective and discretionary, meaning demand can weaken during economic downturns or periods of reduced consumer spending. The company also faces significant competition from both established medical device firms and emerging technologies, and its ability to sustain growth depends on continued product innovation and physician adoption.
Regulatory factors are another consideration: InMode's products must maintain clearance or approval in the markets where they are sold, and changes in reimbursement, labeling, or clinical standards could affect adoption. Additionally, as a company headquartered in Israel, InMode is exposed to regional and geopolitical risks, as well as currency fluctuations from its international sales. Its financial results have also shown sensitivity to shifts in spending by aesthetic practices, which can make revenue growth uneven from year to year.
Conclusion
InMode Ltd. stands out as a specialized medical technology company that has built a global franchise around proprietary radio frequency technology for minimally invasive aesthetic and medical procedures. Its combination of an innovative product portfolio, recurring consumable revenue, and a strong, cash-rich financial profile makes it a distinctive name in the healthcare sector. At the same time, its exposure to discretionary spending and a competitive industry means its performance can vary with broader economic conditions. For investors seeking to understand the medical aesthetics space, INMD remains a relevant and closely followed company.
Exploring Tickeron’s AI Tools for Research
In my own work, Tickeron’s AI Screener has become a useful part of the process for reviewing stocks like this one. It helps surface ideas based on technical indicators, fundamentals, and industry filters, which can save time when comparing opportunities. I find it particularly helpful for confirming patterns in recurring revenue businesses before digging deeper into the filings. The platform supports a range of customizable approaches that align with different strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
INMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 26, 2026
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 42 cases where INMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INMD's RSI Oscillator exited the oversold zone, 27 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on INMD as a result. In 68 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for INMD just turned positive on November 11, 2026. Looking at past instances where INMD's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
Following a +3.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMD advanced for three days, in 164 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 50-day moving average for INMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for INMD entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.219) is normal, around the industry mean (4.142). P/E Ratio (10.750) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.452) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of minimally-invasive aesthetic medical products
Industry MedicalNursingServices
Advertisement